INTRODUCTION
A paradigm for non-invasive imaging of transgene expression involves the appropriate combination of a reporter gene and a reporter substrate or probe [1] [2] [3] . This imaging paradigm is essentially an in vivo radiotracer enzyme assay, where the reporter gene product (an enzyme) selectively converts a reporter probe into a metabolite that is trapped within the transduced cells. Model systems have been established and validated in tissue culture and experimental animals using herpes simplex virus type-1 thymidine kinase (HSV1-tk) gene as a reporter gene and radiolabeled pyrimidine nucleoside analogs and acycloguanosine analogs as reporter probes [4] [5] [6] [7] [8] [9] [10] . The use of this paradigm and the reporter gene technology have been extended. Reporter genes can be used (i) to image vector targeting and level of suicide gene (HSV1-tk) expression 11 ; (ii) to image the regulation of endogenous genes and signal-transduction pathways [12] [13] [14] [15] [16] ; and (iii) to monitor and quantitatively assess the expression of a second transgene that is cis-linked to the reporter gene by an internal ribosome entry site sequence 14, 15 .
We developed the acycloguanosine derivatives [ 18 (Fig. 1) , for positron emission tomography (PET) imaging of HSV1-tk gene expression [17] [18] [19] [20] [21] [22] . We have investigated these pyrimidine and guanosine analogs in human colon cancer cells to compare their efficacies [6] [7] [8] 18, [20] [21] [22] . The pyrimidine derivatives have been found to have two advantages over the acycloguanosine derivatives. First, pyrimidine nucleosides are much more (log-order) sensitive than the guanosine derivatives [ 18 4, 20 . Second, pyrimidine derivatives follow renal clearance 20 , and therefore the background activity is negligible, whereas [ 18 F]FHBG is cleared through a hepatobiliary pathway, resulting in the retention of large amounts of radioactivity in the intestine and other organs 13, 16 . Among the pyrimidine nucleosides, [ 18 F]FFAU has the highest sensitivity and specificity for HSV1-tk, and FEAU has lower sensitivity and specificity than FFAU in HT-29 cells 22 . Other than FFAU and FEAU, pyrimidine analogs have some non-specific uptake 22 . These results suggest that FFAU and FEAU are the imaging agents most specific for HSV1-tk. However, when we compared these tracers in human breast cancer cells (MDA-MB-468), total uptake of [ 18 F]FFAU in HSV1-tk-expressing cells was 150-fold less than that of FEAU 23 . This result suggests that [ 18 F]FEAU may be the best choice of PET imaging agent for HSV1-tk gene expression in terms of sensitivity and specificity; however, further studies are necessary to investigate the efficacy of these nucleosides in a variety of cancer cells. Recently, others have demonstrated that FEAU has the highest uptake ratio between tk-positive transduced cells and wild-type cells when compared with FHBG, FIAU, FMAU, FHPG and FLT 24 . It has been reported that a combination of high accumulation and high selectivity for both HSV1-tk and HSV1-sr39tk makes FEAU a promising candidate for PET imaging of HSV-tk gene expression 25 . [ 18 F]FEAU has also been used to monitor the response of tumors using PETafter systemic Sindbis/tk (vector) treatment as a basis for determining the levels of tissue distribution of vectors in living animals 26 . Bacteriophages (phages) are bacterial viruses that can be adapted to transduce mammalian cells by targeting to a specific receptor [27] [28] [29] [30] [31] [32] . We have recently developed and evaluated a novel phage-based targeted vector, a genetic chimera of filamentous phage and recombinant AAV (termed AAVP) 28 . We have demonstrated that it is possible to assess targeted AAVP vectors non-invasively in experimental tumors. The expression of the reporter gene (HSV1-tk) can be successfully imaged using [ 18 F]FEAU and PET in pre-clinical tumor models 28 . This protocol covers the following aspects of this approach. (i) Radiotracer ([ 18 F]FEAU) production is a seven-step synthesis, shown schematically in Figure 2. (ii) This is followed by radiotracer dosing and administration. (iii) Animal preparation and tumor growth: use nine mice per group to generate statistically meaningful results. Animals are divided into two groups, with group 1 receiving targeted AAVP vector and group 2 receiving non-targeted AAVP vector administration. Negative control groups consist of mice with tumors produced from parental tumor cells; positive controls are mice with tumors produced from tumor cells stably transfected with HSV1-tk. (iv) After micro-PET calibration, the animals are imaged using [ 18 . RGD-4C AAVP-HSV1 vector 28 . Non-targeted AAVP-HSV1-tk vector 28 
EQUIPMENT
. Round-bottomed flasks (100 ml and other sizes) . Pear-shaped flask (15 ml) . V REAGENT SETUP Compound 2 Preparation of compound 2 is performed in the cyclotron area using an FDG box (GE) or similar. K 2 CO 3 /kryptofix solution Prepare a stock solution of K 2 CO 3 /kryptofix 2.2.2 by mixing a solution of kryptofix 2.2.2 (12 mg ml À1 in MeCN) and K 2 CO 3 (2.75 mg ml À1 in water) in a ratio of 80:20 (vol/vol), and store this solution in a refrigerator as a shelf reagent for routine use (discard after 6 months). Standard solution of cold FEAU Prepare a stock solution of cold FEAU, 1 mg ml À1 HPLC solvent (10% MeCN in water), and store this solution in a refrigerator. FEAU can be synthesized according to the previously reported method 35, 36 or following the synthetic scheme in Figure 2 . Cells Any cancer cells can be used 7, 8, 18 . For phage vector-targeted studies, we have used the following cell lines: Kaposi's sarcoma KS1767 (ATCC, Manassas, VA), EF43-FGF4 mouse mammary tumor cells, DU145 prostate carcinoma cells and UC3 bladder carcinoma cells 28 . The Kaposi's sarcoma cells were maintained in MEM; the other cell lines were cultured in DMEM. All media were supplemented with 10% FBS (Gibco), L-GIn and penicillin/streptomycin. All the tumors established by these cells in mice responded to systemic administration of targeted RGD-4C AAVP-HSV1-tk. Animals To induce s.c. tumors, use athymic or nude mice. We used either female (6-week-old) mice for stably transduced tumor implantation with HT-29 cells or male (1-month-old) mice for AAVP vector HSV1-tk gene expression studies. m CRITICAL Approval of the protocol by the appropriate Institutional Animal Care and Use Committee is required. EQUIPMENT SETUP Semi-automated chemistry box (custom made, Fig. 3 ) used for preparation of compounds 3, 5 and 6 (Fig. 2) . Check the gas flow from the argon or nitrogen tank through the box to ensure that all lines are clear and there is no leak in the system. Upload HBr/acetic acid, toluene (0.5 ml), compound 4, NaOMe/MeOH (0.4 ml) and HPLC solvent (10% MeCN/water, 1.2 ml, containing 0.1 ml 1 N HCl) in the reserve vials. HPLC The production of [ 18 F]FEAU requires two HPLC systems, each with a UV detector (e.g., Waters or Agilent) and a radioactivity detector (Bioscans, Washington, DC). One system is for purification and the other is for quality control analysis. UV wavelength is 254 nm. HPLC columns On the day of the experiment, equilibrate HPLC columns, both semi-preparative and analytical, with the appropriate HPLC solvent (10% MeCN/water) before starting the radiosynthesis of [ 18 F]FEAU. Set up the UV lamp at 254 nm. Inject the cold standard solution of FEAU into the HPLC, elute (isocratic) with 10% MeCN solvent (4 ml min À1 , semi-preparative; 1 ml min À1 , analytical) and record the retention time of FEAU in both the semi-preparative and analytical HPLC systems. High-vacuum pump Set up the high vacuum pump with the cooling trap filled with dry ice and isopropanol. Micro-PET scanner Calibrate the micro-PET animal scanner (Concord Microsystems, R-4) according to the manufacturer's protocol. 2| Add trifluoromethane sulfonic anhydride (1.3 equiv.), stir the solution for 15 min at 0 1C, warm to room temperature (B22 1C) and continue stirring for another hour. Monitor the reaction by TLC as follows: transfer a small aliquot of the reaction mixture using a dry syringe to a small flask, pump off pyridine under vacuum and re-dissolve in CH 2 Cl 2 . Spot the solution using a capillary tube on the TLC plate and develop the plate in a developing jar using 15% EtOAc/hexane (vol/vol). Check the plate under a UV lamp. The R f values are 0.4 for the starting material and 0.5 for the product.
3| When the reaction is complete (by TLC), remove pyridine using a vacuum pump, chromatograph the crude product on a silica gel column (20 Â 3 cm, approximately 100 g) and elute the column with 15% EtOAc/hexane at a flow rate of 20 ml min À1 .
4| Collect fractions (10 ml) until the compound is completely eluted (check fractions by spotting on a silica gel plate and visualizing under a UV lamp).
5|
Combine the fractions that match with the product (R f ¼ 0.5) in a round-bottomed flask and evaporate solvent using a rotary evaporator. 
7| Check the identity of the white solid product using 1 H NMR and 19 F NMR spectroscopy, and compare the results with those reported previously 34, 35 (see analytical data).
8| Divide the product into 5-mg aliquots in small vials and seal the vials under argon. ' PAUSE POINT Store the precursor at 4 1C in a desiccator for future radio-fluorination. ? TROUBLESHOOTING Radiotracer ([ 18 F]FEAU) production: preparation of 2,4-bis-trimethylsilyl-5-ethyl uracil 4 9| Weigh 50 mg 5-ethyl uracil and transfer to a pear-shaped flask (15 ml) under argon. MeCN (1.0 ml), 1,1,1,3,3,3 -hexamethyldisilazane (0.5 ml) and TMSCl (0.5 ml) into the flask. 23| Pass the reaction mixture through the Sep-Pack cartridge and discard the eluent (Fig. 3) .
10| Add
24| Connect the Sep-Pack to a second v-vial (Fig. 3) . Elute the product with EtOAc (2 ml) into the pre-crimped v-vial (Fig. 3) . 26| Add 1,2-dichloroethane (0.4 ml) and HBr in AcOH (30%, 0.1 ml) to the dry compound 2 (through the semi-automated box system or by manual addition using manipulators), and heat the mixture for 10 min at 80 1C in a heating block.
27|
Evaporate the solvent to 50% by volume under a stream of argon. Add 0.5-0.7 ml toluene (through the semi-automated box) and continue evaporation to dryness (visual inspection). 32| Inject the crude product onto the semi-preparative column (through the semi-automated box system or by manual addition using manipulators) pre-equilibrated with 10% MeCN/water and purify the product using HPLC. Elute the column with 10% MeCN/water at a flow rate of 4 ml min À1 . Collect the appropriate fraction with similar retention time to the standard FEAU (follow radioactive peak) into a flask to obtain the desired product [ 18 F]FEAU 6 (Fig. 4) .
33| Evaporate solvent on a rotary evaporator, re-dissolve the product in saline (2-5 ml, depending on the desired activity concentration) and filter through a Millipore filter for dose preparation.
34| Measure radioactivity on a dose calibrator (Capintec), calculate activity concentration in each dose, analyze the product on an analytical HPLC for QC and then inject the product with standard cold compound to establish its identity and purity (Fig. 5) . ? TROUBLESHOOTING Radiotracer dosing and administration 35| Prepare the radiotracer, either [ 18 F]FDG or [ 18 F]FEAU, at a concentration of 2 mCi ml À1 (74 MBq ml À1 ) in saline to inject the animals for PET imaging. For autoradiography, prepare a solution at a concentration of 5 mCi ml À1 (185 MBq ml À1 ). ! CAUTION Radioactive, should be performed in a hot cell or behind lead shielding.
Animal preparation and tumor growth 36| Anesthetize animals (nine mice per group) by gas inhalation (2% vol/vol isoflurane in oxygen) and inject (s.c.) tumor cells of interest into the deltoid muscle area of each mouse. This will produce tumor xenografts located away from urinary system (particularly bladder), thus avoiding artifacts caused by accumulation of high activity in urine. To generate xenografts, use a tumor cell dose adequate for each line.
37| When the tumor xenograft is approximately 0.5 cm in diameter, inject a single i.v. dose of RGD-4C AAVP-HSV-tk as described in an accompanying protocol 28, 33 . 38| Take another group of tumor-bearing mice (n ¼ 9) and inject them with non-targeted AAVP-HSV-tk. This group will serve as the experimental control.
Animal imaging on a micro-PET using radiotracer (day 4 after AAVP 42| Place the animal on the scanner bed on a warming pad to maintain thermal regulation, and continue administration of the anesthetic gas so that the animal cannot move during scanning. If the animal moves during imaging, clean images cannot be obtained.
43|
Image the animals at 1 h after injection (static 15-min acquisition).
44| After scanning, remove the animal from the scanner bed and image the next animal. Continue imaging all animals in the same way. Change the absorbing pad after each animal imaging session. 46| Image all animals again on day 7 and day 10 after the injection of the AAVP to determine when maximum gene expression occurs. Image reconstruction, analysis and interpretation 48| Reconstruct images using a standard reconstruction protocol such as the ordered subset expectation maximization algorithm (number of iterations ¼ 4; number of subsets ¼ 16) with 2D mode, without back filter.
47|
49| Estimate regional tumor radioactivity concentrations (kBq cm À3 ) from the maximum pixels within regions of interest drawn around the tumor on transaxial slices of the reconstructed image sets. 51| Calculate the mean level of activity uptake and s.d. Compare the control tissue (muscle in opposite deltoid area) and tumors. Calculate the tumor/muscle radiotracer uptake ratio between tumor and muscle by dividing the radioactivity concentration in the tumor by the radioactivity concentration in the muscle in the same animal. Calculate erythematic mean and s.d. of animal groups. In the case of non-Gaussian distribution and difference in inter-group variances, calculate medians and ranges instead.
52| Use two-tailed Student's t-test to compare unrelated (independent) groups with equal variances (F-test) and Gaussian distribution of parameters; otherwise, use non-parametric tests (e.g., Mann-Whitney U-test) to compare control and treated groups.
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